(Q34596369)

3 August 2017

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer (English)

1 reference

3 August 2017

phase II clinical trial

0 references

1 reference

1 reference

1 reference

James Lewis Abbruzzese

5

object named as

James L Abbruzzese

1 reference

3 August 2017

Henry Q Xiong

1

1 reference

3 August 2017

Gauri R Varadhachary

2

1 reference

3 August 2017

Joan C Blais

3

1 reference

3 August 2017

Kenneth R Hess

4

1 reference

3 August 2017

Robert A Wolff

6

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

3 August 2017

1 reference

3 August 2017

113

1 reference

3 August 2017

2046-2052

1 reference

3 August 2017

8

1 reference

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

3 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Prognostic factors in patients with gemcitabine-refractory pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23810

7 January 2021

Identifiers

DOI

10.1002/CNCR.23810

1 reference

release_664izuabxjezhftkelm23tnwum

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/664izuabxjezhftkelm23tnwum

24 November 2022

mapped directly with Wikidata item

1 reference